Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging
<p>Breakthrough Nine-Amino-Acid Peptide Designed to Restore the Immune System's Ability to Eliminate Senescent Cells, With Clinical Entry Planned for 2026 MIAMI, Oct. 12, 2026 /PRNewswire/ -- Immorta Bio, Inc., a biotechnology company pioneering therapies targeting fundamental mechanisms of...</p>
Read original article ↗
Related Articles
No Man’s Sky is coming to the iPhone and iPad
The No Man's Sky universe is about to get a little bit smaller - but in a good way. Hello Games announced that its long-
Intel to phase out SGX after Xeon Diamond Rapids in favor of TDX
Intel set to discontinue SGX after Xeon 'Diamond Rapids' and focus on expanding TDX capabilities to meet emerging securi
Transaction brings Finia's technology and experience serving micro-businesses to PayJoy's global platform SAN FRANCISCO,
Fedstack, a Smoothstack Company, Named an OpenAI Select Partner
Partnership advances how Fedstack develops software engineers prepared to put AI to work across government technology. M